Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations

Expert Review of Cardiovascular Therapy

Volumn 14, Issue 12, 2016, Pages 1335-1347

  Fruhwald, Sonja ^a   Pollesello, Piero ^b   Fruhwald, Friedrich ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b ORION CORPORATION   (Finland)

Author keywords

ethics; Heart failure; inodilator; kidney function; levosimendan; palliative care; quality of life

Indexed keywords

LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADVERSE OUTCOME; CARDIAC PATIENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG USE; ETHICAL DECISION MAKING; FAMILY FUNCTIONING; FUNCTIONAL STATUS; HEALTH CARE NEED; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LIFE EXPECTANCY; MEDICAL ETHICS; MENTAL FUNCTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PALLIATIVE THERAPY; PHARMACODYNAMICS; PHYSICAL CAPACITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIGION; REVIEW; RISK ASSESSMENT; SOCIAL ASPECTS AND RELATED PHENOMENA; TERMINAL CARE; HEART ASSIST DEVICE; PATHOPHYSIOLOGY;

CARDIOTONIC AGENTS; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; HYDRAZONES; PYRIDAZINES; QUALITY OF LIFE;

EID: 84996508850     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1080/14779072.2016.1247694     Document Type: Review

References (112)

1. Farré N, Vela E, Clèries M, et al. Medical resource use and expenditure in patients with chronic heart failure:a population-based analysis of 88 195 patients. Eur J Heart Fail. 2016;18:1132–1140. published online 2016 Apr25. DOI:10.1002/ejhf.549
2. Norton C, Georgiopoulou VV, Kalogeropoulos AP, et al. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis. 2011;54:78–85.
3. Franzén-Dahlin A, Karlsson MR, Mejhert M, et al. Quality of life in chronic disease:a comparison between patients with heart failure and patients with aphasia after stroke. J Clin Nurs. 2010;19:1855–1860.
4. Pearse SG, Cowie MR., Sleep-disordered breathing in heart failure. Eur J Heart Fail. 2016;18:353–361.
5. Sokoreli I, de Vries JJ, Pauws SC, et al. Depression and anxiety as predictors of mortality among heart failure patients:systematic review and meta-analysis. Heart Fail Rev. 2016;21:49–63.
6. Lum HD, Carey EP, Fairclough D, et al. Burdensome physical and depressive symptoms predict heart failure-specific health status over one year. J Pain Symptom Manage. 2016;51:963–970.
7. Byrne M, Doherty S, Murphy AW, et al. The CHARMS study:cardiac patients’ experiences of sexual problems following cardiac rehabilitation. Eur J Cardiovasc Nurs. 2013;12:558–566.
8. Driel AG, de Hosson MJ, Gamel C. Sexuality of patients with chronic heart failure and their spouses and the need for information regarding sexuality. Eur J Cardiovasc Nurs. 2014;13:227–234.
9. Kraai IH, Vermeulen KM, Luttik ML, et al. Preferences of heart failure patients in daily clinical practice:quality of life or longevity? Eur J Heart Fail. 2013;15:1113–1121.
10. Levine BS. Intermittent positive inotrope infusion in the management of end-stage, low-output heart failure. J Cardiovasc Nurs. 2000;14:76–93.
11. Toma M, Starling RC. Inotropic therapy for end-stage heart failure patients. Curr Treat Options Cardiovasc Med. 2010;12:409–419.
12. Greco T, Calabrò MG, Covello RD, et al. A Bayesian network meta-analysis on the effect of inodilatory agents on mortality. Br J Anaesth. 2015;114:746–756.
13. Adams KF, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J. 1998;135:S204–S215.
14. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure:a position statement from the study group of advanced heart failure of the heart failure association of the European society of cardiology. Eur J Heart Fail. 2007;9:684–694.• Guideline statement.
15. Nieminen MS, Altenberger J, Ben-Gal T, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure:clinical evidence, practical considerations, and perspectives:an expert panel consensus. Int J Cardiol. 2014;174:360–367.• Systematic review.
16. Hoekstra T, Jaarsma T, van Veldhuisen DJ, et al. Quality of life and survival in patients with heart failure. Eur J Heart Fail. 2013;15:94–102.
17. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–2018.
18. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation:29th official adult heart transplant report-2012. J Heart Lung Transplant. 2012;31:1052–1064.
19. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–1443.
20. Estep JD, Starling RC, Horstmanshof DA, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients:results from the ROADMAP study. J Am Coll Cardiol. 2015;66:1747–1761.
21. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates:results of the INTrEPID trial. J Am Coll Cardiol. 2007;50:741–747.
22. Pollesello P, Parissis J, Kivikko M, et al. Levosimendan meta-analyses:is there a pattern in the effect on mortality? Int J Cardiol. 2016;209:77–83.
23. Szilágyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004;486:67–74.
24. Yokoshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249–259.
25. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68:807–812.
26. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study):a randomized double-blind trial. Lancet. 2002;360:196–202.
27. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102:2222–2227.
28. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103–112.
29. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure:the SURVIVE randomized trial. JAMA. 2007;297:1883–1891.
30. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903–1912.
31. Lilleberg J, Laine M, Palkama T, et al. Duration of the hemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75–82.
32. Nieminen MS, Dickstein K, Fonseca C, et al. The patient perspective:quality of life in advanced heart failure with frequent hospitalisations. Int J Cardiol. 2015;191:256–264.•• International consensus on quality of life and trade-off.
33. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81–86.
34. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine:outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11:304–311.
35. Bergh CH, Andersson B, Dahlström U, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010 Apr;12(4):404–410.
36. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on hemodynamic, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660–668.
37. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522–531.
38. Stevenson LW. Clinical use of inotropic therapy for heart failure:looking backward or forward? Part I:inotropic infusions during hospitalization. Circulation. 2003;108:367–372.
39. Stevenson LW. Clinical use of inotropic therapy for heart failure:looking backward or forward? Part II:chronic inotropic therapy. Circulation. 2003;108:492–497.
40. Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol. 2004;93:1309–1312.
41. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40:634–646.
42. Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
43. Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study:a multicentre randomized trial. Eur J Heart Fail. 2014;16:898–906.
44. Nanas JN, Papazoglou P, Tsagalou EP, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol. 2005;95:768–771.
45. Bonios MJ, Terrovitis JV, Drakos SG, et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol. 2012;159:225–229.
46. Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. 2006;92:1768–1772.
47. Mavrogeni S, Giamouzis G, Papadopoulou E, et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail. 2007;13:556–559.
48. Papadopoulou EF, Mavrogeni SI, Dritsas A, et al. Assessment of quality of life using three different activity questionnaires in heart failure patients after monthly, intermittent administration of levosimendan during a six-month period. Hell J Cardiol. 2009;50:269–274.
49. Kleber FX, Bollmann T, Borst MM, et al. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension:results of a pilot study. J Clin Pharmacol. 2009;49:109–115.
50. Malfatto G, Della Rosa F, Villani A, et al. Intermittent levosimendan infusions in advanced heart failure:favorable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol. 2012;60:450–455.
51. Berger R, Moertl D, Huelsmann M, et al. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail. 2007;9:202–208.
52. Parle NM, Thomas MD, Dembo L, et al. Repeated infusions of levosimendan:well tolerated and improves functional capacity in decompensated heart failure—a single-centre experience. Heart Lung Circ. 2008;17:206–210.
53. Silvetti S, Greco T, Di Prima AL, et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients:meta-analysis of randomized trials. Clin Res Cardiol. 2014;103:505–513.
54. Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure:a systematic review and metaanalysis of randomized controlled trials. Intensive Care Med. 2012;38:359–367.
55. Nony P, Boissel JP, Lievre M, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol. 1994;46:191–196.
56. von Scheidt W, Pauschinger M, Ertl G. Long-term intravenous inotropes in low-output terminal heart failure? Clin Res Cardiol. 2016;105:471–481.
57. Comín-Colet J. Multicenter, double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of intermittent levosimendan in outpatients with advanced chronic heart failure:the LION Heart Study. Presented at “Late Breaking Trials II:Heart Failure Management”, Heart FAILURE 2015 Congress of the ESC-HFA; 2015 May 24; Seville, Spain. [cited 2016 Aug 25]. Available from:http://spo.escardio.org/SessionDetails.aspx?eevtid=1077&sessId=14858#.VWatraM3ups
58. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes:report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31:703–711.•• Excellent consensus opinion.
59. Damman K, Testani JM. The kidney in heart failure:an update. Eur Heart J. 2015;36:1437–1444.
60. Waldum-Grevbo B. What physicians need to know about renal function in outpatients with heart failure. Cardiology. 2015;131:130–138.
61. Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure. Eur Heart J. 2012;33:2135–2142.
62. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–869.
63. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure:comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431–435.
64. Hou ZQ, Sun ZX, Su CY, et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovasc Ther. 2013;31:108–114.
65. Rafouli-Stergiou P, Parissis JT, Farmakis D, et al. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment. J Cardiovasc Med (Hagerstown). 2015. published online 2015 Jan31. DOI:10.2459/JCM.0000000000000244
66. Zorlu A, Yucel H, Yontar OC, et al. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function. Arq Bras Cardiol. 2012;98:537–543.
67. Knezevic I, Poglajen G, Hrovat E, et al. The effects of levosimendan on renal function early after heart transplantation:results from a pilot randomized trial. Clin Transplant. 2014;28:1105–1111.
68. Silva-Cardoso J, Ferrreira J, Oliveira-Soares A, et al. Effectiveness and safety of levosimendan in clinical practice. Rev Port Cardiol. 2009;28:143–153.
69. Zemljic G, Bunc M, Yazdanbakhsh AP, et al. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail. 2007;13:417–421.
70. Yilmaz MB, Yontar C, Erdem A, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels. 2009;24:16–21.
71. Caira C, Brasolin B, Maestrini V, et al. Effects of Levosimendan on renal function and renal hemodynamic parameters in patients with acute heart failure. Eur J Heart Fail Suppl. 2007;6:103.
72. Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure:possible underlying mechanisms. Eur J Heart Fail. 2014;16:281–288.
73. Russ MA, Prondzinsky R, Carter JM, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock:improvement with levosimendan. Crit Care Med. 2009;37:3017–3023.
74. Parissis JT, Paraskevaidis I, Bistola V, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98:1489–1492.
75. Poelzl G, Zwick RH, Grander W, et al. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz. 2008;33:368–373.
76. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions—insights from the ESCAPE trial. J Am Coll Cardiol. 2007;51:1268–1274.
77. Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure:an updated meta-analysis. Int J Cardiol. 2016;202:138–143.
78. Parissis JT, Papadopoulos C, Nikolaou M, et al. Effects of levosimendan on QoL and emotional stress in advanced heart failure patients. Cardiovasc Drugs Ther. 2007;21:263–268.
79. Fedele F, Bruno N, Brasolin B, et al. Cost-effectiveness of levosimendan in patients with acute heart failure. J Cardiovasc Pharmacol. 2011;58:363–366.
80. Lucioni C, D’Ambrosi A, Mazzi S, et al. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy. Adv Ther. 2012;29:1037–1050.
81. Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure –the PERSIST study. Eur J Heart Fail. 2008;10:1246–1254.
82. Hunt SA, Abraham WT, Mh C, et al.; ACC/AHA. guideline update for the diagnosis and management of chronic heart failure in the adult:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure):developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation:endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235.• Guideline.
83. Rosenwax L, Spilsbury K, McNamara BA, et al. A retrospective population based cohort study of access to specialist palliative care in the last year of life:who is still missing out a decade on? BMC Palliat Care. 2016;15:46.
84. Wachterman MW, Pilver C, Smith D, et al. Quality of end-of-life care provided to patients with different serious illnesses. JAMA Intern Med. 2016;176:1095–1102.
85. McIlvennan CK, Allen LA. Palliative care in patients with heart failure. Br Med J. 2016;353:i1010.
86. Malhotra C, Sim DK, Jaufeerally F, et al. Impact of advance care planning on the care of patients with heart failure:study protocol for a randomized controlled trial. Trials. 2016;17:285.
87. Hollander SA, Axelrod DM, Bernstein D, et al. Compassionate deactivation of ventricular assist devices in pediatric patients. J Heart Lung Transplant. 2016;35:564–567.
88. Etkind SN, Bristowe K, Bailey K, et al. How does uncertainty shape patient experience in advanced illness? A secondary analysis of qualitative data. Palliat Med. 2016. published online 2016 Apr29. DOI:10.1177/0269216316647610
89. Blachman NL, Blaum CS. Integrating care across disciplines. Clin Geriatr Med. 2016;32:373–383.
90. Martín-Lesende I, Recalde E, Viviane-Wunderling P, et al. Mortality in a cohort of complex patients with chronic illnesses and multimorbidity:a descriptive longitudinal study. BMC Palliat Care. 2016;15:42.
91. Van Scoy LJ, Green MJ, Dimmock AE, et al. High satisfaction and low decisional conflict with advance care planning among chronically ill patients with advanced chronic obstructive pulmonary disease or heart failure using an online decision aid_ a pilot study. Chronic Illn. 2016;12:227–235. published online 2016 Apr6. DOI:10.1177/1742395316633511
92. Bekelman DB, Rabin BA, Nowels CT, et al. Barriers and facilitators to scaling up outpatient palliative care. J Palliat Med. 2016;19:456–459.
93. Wong FK, Ng AY, Lee PH, et al. Effects of a transitional palliative care model on patients with end-stage heart failure:a randomized controlled trial. Heart. 2016;102:1100–1108.
94. LaDonna KA, Bates J, Tait GR, et al. ‘Who is on your health-care team?’ Asking individuals with heart failure about care team membership and roles. Health Expect. 2016. published online 29Feb 2016. DOI:10.1111/hex.12447
95. Denvir MA, Cudmore S, Highet G, et al. Phase 2 randomised controlled trial and feasibility study of future care planning in patients with advanced heart disease. Sci Rep. 2016;6:24619.
96. Man WD, Chowdhury F, Taylor RS, et al. Building consensus for provision of breathlessness rehabilitation for patients with chronic obstructive pulmonary disease and chronic heart failure. Chron Respir Dis. 2016;13:229–239.
97. Adler ED, Goldfinger JZ, Kalman J, et al. Palliative care in the treatment of advanced heart failure. Circulation. 2009;120:2597–2606.
98. Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure:a scientific statement from the American Heart Association. Circulation. 2012;125:1928–1952.
99. Beauchamp TL, Childress JF. Principles of biomedical ethics. 6th ed. New York, NY:Oxford University Press; 2009. p. 38–39.
100. Khalaila R. Patients’ family satisfaction with needs met at the medical intensive care unit. J Adv Nurs. 2013;69:1172–1182.
101. Aslakson RA, Curtis JR, Nelson JE. The changing role of palliative care in the ICU. Crit Care Med. 2014;42:2418–2428.
102. Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life:associations with end-of-life conversations. Arch Intern Med. 2009;169:480–488.
103. Friesenecker B, Fruhwald S, Hasibeder W, et al. [Definitions, decision-making and documentation in end of life situations in the intensive care unit]. Anästhesiol Intensivmed Notfallmed Schmerzther. 2013;48:216–223. German.
104. Sykes N, Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol. 2003;4:312–318.
105. Boland JW, Ziegler L, Boland EG, et al. Is regular systemic opioid analgesia associated with shorter survival in adult patients with cancer? A systematic literature review. Pain. 2015;156:2152–2163.
106. Goodlin SJ, Wingate S, Albert NM, et al. Investigating pain in heart failure patients:the pain assessment, incidence, and nature in heart failure (PAIN-HF) study. J Card Fail. 2012;18:776–783.
107. Mentz J, Tulsky JA, Granger BB, et al. The palliative care in heart failure trial:rationale and design. Am Heart J. 2014;168:645–651.
108. George S, Leasure AR. Application of transformational leadership principles in the development and integration of palliative care within an advanced heart failure program. Dimens Crit Care Nurs. 2016;35:59–65.
109. Yu DS, Chan HY, Leung DY, et al. Symptom clusters and quality of life among patients with advanced heart failure. J Geriatr Cardiol. 2016;13:408–414.
110. El-Jawahri A, Paasche-Orlow MK, Matlock D, et al. Randomized, controlled trial of an advance care planning video decision support tool for patients with advanced heart failure. Circulation. 2016;134:52–60.
111. Knox L, Rahman RJ, Beedie C. Quality of life in patients receiving telemedicine enhanced chronic heart failure disease management:a meta-analysis. J Telemed Telecare. 2016. published online 2016 Jul22. pii:1357633X16660418.
112. Piotrowicz E, Piepoli MF, Jaarsma T, et al. Telerehabilitation in heart failure patients:the evidence and the pitfalls. Int J Cardiol. 2016;220:408–413.